BRPI0817269A2 - Análogos de azacitidina e usos dos mesmos - Google Patents

Análogos de azacitidina e usos dos mesmos

Info

Publication number
BRPI0817269A2
BRPI0817269A2 BRPI0817269-2A2A BRPI0817269A BRPI0817269A2 BR PI0817269 A2 BRPI0817269 A2 BR PI0817269A2 BR PI0817269 A BRPI0817269 A BR PI0817269A BR PI0817269 A2 BRPI0817269 A2 BR PI0817269A2
Authority
BR
Brazil
Prior art keywords
azacitidine
analogs
azacitidine analogs
Prior art date
Application number
BRPI0817269-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Lewis Silverman
James Holland
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of BRPI0817269A2 publication Critical patent/BRPI0817269A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI0817269-2A2A 2007-09-26 2008-09-25 Análogos de azacitidina e usos dos mesmos BRPI0817269A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077669 WO2009042766A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0817269A2 true BRPI0817269A2 (pt) 2014-10-07

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0817269-2A2A BRPI0817269A2 (pt) 2007-09-26 2008-09-25 Análogos de azacitidina e usos dos mesmos
BRPI0817234-0A2A BRPI0817234A2 (pt) 2007-09-26 2008-09-25 Análogos de azacitidina e seus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0817234-0A2A BRPI0817234A2 (pt) 2007-09-26 2008-09-25 Análogos de azacitidina e seus usos

Country Status (15)

Country Link
US (2) US8399420B2 (enExample)
EP (2) EP2205073A4 (enExample)
JP (2) JP2010540556A (enExample)
KR (2) KR20100072230A (enExample)
CN (2) CN101815437A (enExample)
AU (2) AU2008304380A1 (enExample)
BR (2) BRPI0817269A2 (enExample)
CA (2) CA2700267A1 (enExample)
IL (1) IL204690A0 (enExample)
MX (2) MX2010003261A (enExample)
NZ (2) NZ583824A (enExample)
RU (1) RU2488591C2 (enExample)
UA (2) UA99308C2 (enExample)
WO (2) WO2009042766A1 (enExample)
ZA (1) ZA201001660B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
US8399420B2 (en) 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
DK3692983T3 (da) 2008-05-15 2021-09-20 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010129211A2 (en) * 2009-04-27 2010-11-11 Dr. Reddy's Laboratories Ltd. Preparation of decitabine
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
WO2014172432A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
SG11201705069YA (en) * 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
CN110446504B (zh) 2017-03-20 2024-07-26 瓦西尼斯公司 用脑信号蛋白-4d抗体联合表观遗传调节剂治疗癌症
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
US20230416294A1 (en) * 2020-08-10 2023-12-28 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (enExample) 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3737456A1 (de) 1986-11-04 1988-05-19 Fuji Photo Film Co Ltd Laserlichtquelle
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
IE980216A1 (en) 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
WO1992015113A1 (en) * 1991-02-19 1992-09-03 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
DE69230563T2 (de) 1991-08-14 2000-09-14 Procter & Gamble Pharmaceuticals, Inc. Oxazolidinon-derivate mit antiarrhythmischer und antifibrillatorische wirkung
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
AU6764396A (en) 1995-08-08 1997-03-05 Thomas Jefferson University Recombinant c-proteinase and processes, methods and uses thereof
WO1997009878A1 (en) 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
ATE196844T1 (de) 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
DK0986570T3 (da) 1997-01-24 2003-07-28 Conpharma As Gemcitabinderivat
DE69813231T2 (de) * 1997-06-03 2003-12-04 Itochu Techno-Chemical Inc., Tokio/Tokyo Natürliche antitumor- oder antivirale substanzen und ihre anwendung
AU1412299A (en) 1997-11-25 1999-06-15 Protarga, Inc. Nucleoside analog compositions and uses thereof
AU2300699A (en) 1998-02-17 1999-08-30 Ono Pharmaceutical Co. Ltd. Amidino derivatives and drugs containing the same as the active ingredient
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
HUP0203142A3 (en) 1999-10-15 2003-03-28 Hoffmann La Roche Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
WO2003044035A1 (de) 2001-11-21 2003-05-30 Ganymed 256 Vermögensverwaltungs Gmbh Phospholipid-derivate von nucleosiden als antitumorale arzneimittel
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
WO2004101593A1 (ja) 2003-05-16 2004-11-25 Kissei Pharmaceutical Co., Ltd. ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20080033172A1 (en) 2003-12-19 2008-02-07 Koronis Pharmaceuticals, Incorporated Mutagenic Heterocycles
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
WO2005075482A1 (en) 2004-02-04 2005-08-18 Neurosearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007035783A2 (en) * 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
US8399420B2 (en) 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof

Also Published As

Publication number Publication date
KR20100102092A (ko) 2010-09-20
WO2009042766A9 (en) 2009-05-28
JP2010540556A (ja) 2010-12-24
CA2700267A1 (en) 2009-04-02
US8399420B2 (en) 2013-03-19
EP2205073A4 (en) 2013-03-06
NZ583824A (en) 2012-06-29
EP2197274A4 (en) 2013-03-06
AU2008304380A1 (en) 2009-04-02
RU2488591C2 (ru) 2013-07-27
BRPI0817234A2 (pt) 2014-09-30
WO2009042767A1 (en) 2009-04-02
CN101877964A (zh) 2010-11-03
RU2010116154A (ru) 2011-11-10
JP2010540555A (ja) 2010-12-24
US8158605B2 (en) 2012-04-17
WO2009042766A1 (en) 2009-04-02
US20090209482A1 (en) 2009-08-20
EP2205073A1 (en) 2010-07-14
KR20100072230A (ko) 2010-06-30
MX2010003002A (es) 2010-07-05
CN101815437A (zh) 2010-08-25
ZA201001660B (en) 2011-05-25
MX2010003261A (es) 2010-08-18
EP2197274A1 (en) 2010-06-23
NZ583923A (en) 2012-05-25
CA2700207A1 (en) 2009-04-02
RU2010116274A (ru) 2011-11-10
US20090209477A1 (en) 2009-08-20
AU2008304381A1 (en) 2009-04-02
UA99836C2 (en) 2012-10-10
UA99308C2 (ru) 2012-08-10
IL204690A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
BRPI0817269A2 (pt) Análogos de azacitidina e usos dos mesmos
NO2022027I1 (no) Combination of daunorubicin and cytarabine
BRPI0922691A2 (pt) conjugados de leptina e análogo de leptina e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0923283A2 (pt) conjugados terapêuticos de peptídeo e usos dos mesmos
BRPI0922689A2 (pt) conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0821310A2 (pt) Conjugados polipeptídeos-ácido nucleico e usos dos mesmos
BRPI0912480A2 (pt) compostos de monoalquiltina de alta pureza e usos dos mesmos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0814599A2 (pt) Pesticidas e usos dos mesmos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0821106A2 (pt) Pró-fármacos de nucleosídeo e usos dos mesmos
BRPI1015918A2 (pt) conjugados de peptídeo multiméricos e usos dos mesmos
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0914891A2 (pt) agonistas de aril gpr119 e usos dos mesmos
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0720494A2 (pt) Dispositivo de suporte vertebral
BRPI1014997A2 (pt) compostos heteroarila e usos dos mesmos
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
DK2066354T3 (da) Norovirus vaccine formuleringer
BRPI0922483A2 (pt) agonista de receptor gpr120 e usos dos mesmos
DK2051744T3 (da) Steriliseringsanordning
BR112012001260A2 (pt) conjugados de epsilon-polilisina e o emprego dos mesmos
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.